Welcome to the Center for Targeted Therapeutics and Translational Nanomedicine
CT3N is a joint interdisciplinary venture between the Perelman School of Medicine (PSOM) and the School of Engineering and Applied Science (SEAS), with the mission to facilitate and accelerate translational research in targeted therapeutics and nanomedicines by bringing together the many leading laboratories active in these areas at the University of Pennsylvania, CHOP and surrounding academic institutions. Research areas being pursued by CT3N faculty include design of biomaterials and carriers for drug delivery, identification of molecular targets for cell-specific delivery, studies of targeting, binding, sub-cellular trafficking and metabolism of targeted drugs.
2026 CT3N Symposium
Details coming soon
Hold the date: December 2, 2026
Missed the 2025 CT3N Symposium?
View the recordings here
CT3N Faculty Publication Highlights
Wang et al., Cell (2025)
Patel et al., Nature Commun. (2025) / Jake Brenner lab
Upcoming Events
Faculty in the News
Future mRNA vaccines may prevent food and seasonal allergies (Drew Weissman)
Friday, September 26, 2025
Reimagined Penn Medicine facility set to usher in a bold new era of Immune Health discovery (J. Wherry)
Friday, September 5, 2025
Researchers unlock safer RNA therapies for inflammatory diseases (Jake Brenner)
Monday, August 11, 2025
Microrobots Navigate Diverse Oral Environments to Deliver Therapies (Daeyeon Lee; Hyun Koo)
Thursday, April 24, 2025
Christopher Murray Elected AAAS Fellow
Thursday, March 27, 2025
Featured Faculty
Noor Momin, PhD, Assistant Professor, Department of Bioengineering, School of Engineering and Applied Science
Dr. Noor Momin is the Stephenson Foundation Term Assistant Professor of Innovation. She completed her Bachelor of Science degree in Biomedical Engineering at the University of Texas at Austin and earned her Ph.D. in Biological Engineering. As a graduate student, Dr. Momin engineered a localization strategy that improves the safety and effectiveness of cytokine therapies used for cancer treatment. This technology is being evaluated in both canine and human clinical trials. She went on to conduct postdoctoral training at Massachusetts General Hospital where she examined the role of leukocytes in arrhythmia. In January of 2024, Dr. Momin launched her independent research group at University of Pennsylvania in the Bioengineering Department and the Penn Center for Precision Engineering for Health. The Momin lab seeks to understand and modulate the immune response for targeted treatment of cardiovascular diseases.